Pegvisomant, developed by professor John Kopchick in 1987, shows potential to make treatment-resistant lung cancer cells more ...

Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 ...

Amini: The systemic landscape is constantly changing and is very exciting. It will only become more complicated for our ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...

The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

Racial disparities persist in receipt of curative treatment for early-stage non-small cell lung cancer (NSCLC), according to a study published online March 2 in JAMA Network Open. Olivia F. Lynch, M.D ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

Amini: I believe this is critical for all stages of NSCLC. Whether you are in a small rural practice, large community or ...

Hernexeos (zongertinib) received FDA accelerated approval for unresectable or metastatic non-squamous NSCLC with HER2 TKD mutations after prior treatment. The Beamion LUNG-1 trial showed a 75% ...